Globus Medical (NYSE:GMED) Issues FY 2026 Earnings Guidance

Globus Medical (NYSE:GMED) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 4.950-5.050 for the period, compared to the consensus EPS estimate of 5.000. The company issued revenue guidance of $3.1 billion, compared to the consensus revenue estimate of $3.2 billion.

Wall Street Analysts Forecast Growth

GMED has been the subject of several recent research reports. UBS Group began coverage on shares of Globus Medical in a report on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 price target for the company. BMO Capital Markets lowered shares of Globus Medical from an “outperform” rating to a “market perform” rating and cut their target price for the company from $94.00 to $78.00 in a research note on Friday. Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 10th. Needham & Company LLC reduced their target price on Globus Medical from $117.00 to $100.00 and set a “buy” rating for the company in a research report on Friday. Finally, Truist Financial reduced their target price on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Thursday, July 16th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $96.92.

Globus Medical Stock Performance

Shares of NYSE:GMED opened at $70.67 on Friday. Globus Medical has a fifty-two week low of $70.39 and a fifty-two week high of $101.40. The firm has a fifty day moving average price of $77.20 and a 200 day moving average price of $83.18. The firm has a market cap of $9.49 billion, a price-to-earnings ratio of 17.36, a P/E/G ratio of 1.28 and a beta of 0.98.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Thursday, November 5th. The medical device company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.20 by $0.03. The firm had revenue of $763.72 million during the quarter, compared to analysts’ expectations of $792.39 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The business’s revenue for the quarter was down .7% on a year-over-year basis. During the same quarter last year, the firm earned $1.18 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, research analysts predict that Globus Medical will post 4.99 earnings per share for the current year.

Insider Activity

In other news, Director Stephen Zarrilli sold 25,000 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total value of $2,176,000.00. Following the sale, the director owned 25,000 shares of the company’s stock, valued at approximately $2,176,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ann Rhoads sold 5,000 shares of the stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $85.00, for a total transaction of $425,000.00. Following the sale, the director directly owned 35,384 shares of the company’s stock, valued at $3,007,640. This represents a 12.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 60,000 shares of company stock valued at $4,838,400. 18.38% of the stock is owned by insiders.

Key Stories Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, offering potential support for shareholder returns. Third-quarter results and repurchase announcement
• Neutral Sentiment: Analyst views were mixed: Canaccord and Needham cut their price targets but maintained Buy ratings, while Wells Fargo slightly raised its target and kept an Overweight rating. The company is also seeking acquisitions, though the provided report does not detail potential deals. Report on acquisition plans
• Negative Sentiment: Revenue of $763.7 million missed the $792.4 million analyst estimate and declined 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion is below the roughly $3.2 billion consensus; management cited spine-product launch delays and weak Nevro sales, weighing on expectations despite EPS guidance being broadly in line. Q3 call highlights and outlook
• Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target, adding to concerns about the outlook. Coverage of the stock decline

About Globus Medical

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.